Orchard Therapeutics PLC
Floni Bajraktari, MSc, is an experienced clinical study manager with a strong background in leading and overseeing clinical trials across various organizations. Currently serving as a Senior Clinical Study Manager at Orchard Therapeutics since October 2022, Floni previously held the role of Senior Clinical Project Manager at Spero Therapeutics, where responsibilities included planning and implementing a Phase 3 pediatric clinical research study and coordinating external vendor activities. Floni's career also includes significant roles at Baim Institute for Clinical Research, Harvard Clinical Research Institute, and Cardiovascular Research Foundation, where Floni demonstrated expertise in clinical project management, data management, and team leadership. Educational qualifications include a Master of Science in Clinical Trials from the University of London and a Bachelor of Science in Biology from the University of Bridgeport.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.